[223Ra] RaCl2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era

• Main Authors: Yang Yang (Author), Luciana Magalhães Rebelo Alencar (Author), Martha Sahylí Ortega Pijeira (Author), Beatriz da Silva Batista (Author), Alefe Roger Silva França (Author), Erick Rafael Dias Rates (Author), Ruana Cardoso Lima (Author), Sara Gemini-Piperni (Author), Ralph Santos-Oliveira (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The treatment of bone metastatsis as primary bone cancer itself is still a challenge. The use od radium dichloride ([223Ra] RaCl2) has emerged in the last few years as one of the best treatment choice for bone cancer, with especial focus in bone metastasis. The alpha-emitter radiopharmaceutical has showed potent and efficient results in several clinical trials. In this study we have formulated radium dichloride ([223Ra] RaCl2) nanomicelles in order to evaluate and compare with pure radium dichloride ([223Ra] RaCl2). The results showed that nanomicelles at the same dose had a superior effect (20% higher efficient) when compared with pure radium dichloride ([223Ra] RaCl2). The results corroborated the effectiveness of the nanosystem validating the application of nanotechnology in alpha-radiotherapy with radium dichloride ([223Ra] RaCl2).

Item Description

1071-7544
1521-0464
10.1080/10717544.2021.2005719